Evidence map›Paper›PMID 39468303›Full record

ReviewEMBO molecular medicine2024

Sepsis-induced changes in pyruvate metabolism: insights and potential therapeutic approaches.

Louise Nuyttens, Jolien Vandewalle, Claude Libert

Abstract readReview
In one paragraph

Review in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Louise NuyttensCenter for Inflammation Research, Vlaams Instituut voor Biotechnologie (VIB), Ghent, Belgium.ORCID 0000-0003-1223-7315
Jolien VandewalleCenter for Inflammation Research, Vlaams Instituut voor Biotechnologie (VIB), Ghent, Belgium.ORCID 0000-0003-1844-6476
Claude LibertCenter for Inflammation Research, Vlaams Instituut voor Biotechnologie (VIB), Ghent, Belgium. claude.libert@irc.vib-ugent.be.ORCID 0000-0001-6408-036X

Funding

Fonds Wetenschappelijk Onderzoek (FWO) 11M3122NFonds Wetenschappelijk Onderzoek (FWO) 1220924NFonds Wetenschappelijk Onderzoek (FWO) 3G014921Fonds Wetenschappelijk Onderzoek (FWO) S003122NUniversiteit Gent (UGent) 01M00121
6 · The paper itself

Abstract

Sepsis is a heterogeneous syndrome resulting from a dysregulated host response to infection. It is considered as a global major health priority. Sepsis is characterized by significant metabolic perturbations, leading to increased circulating metabolites such as lactate. In mammals, pyruvate is the primary substrate for lactate production. It plays a critical role in metabolism by linking glycolysis, where it is produced, with the mitochondrial oxidative phosphorylation pathway, where it is oxidized. Here, we provide an overview of all cytosolic and mitochondrial enzymes involved in pyruvate metabolism and how their activities are disrupted in sepsis. Based on the available data, we also discuss potential therapeutic strategies targeting these pyruvate-related enzymes leading to enhanced survival.

Indexed as

Pyruvic AcidSepsisAnimalsGlycolysisHumansMitochondriaOxidative PhosphorylationPyruvic AcidLactateMetabolismMitochondriaPyruvateSepsis

Identifiers

PMID39468303
PMCPMC11554794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.